Skip to content

KLRS KLRS Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Merck & Co. logo
Merck & Co.MRK
-$10.21B-587%
Amgen logo
AmgenAMGN
-$716M-60.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$59.05M+49.4%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$4.66M-141%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's investing cash flow?
KLRS (KLRS) reported investing cash flow of -$50.35M in Q1 2026.
How has KLRS's investing cash flow changed year-over-year?
KLRS's investing cash flow decreased by 921.1% year-over-year, from -$4.93M to -$50.35M.
What is the long-term trend for KLRS's investing cash flow?
Over 2 years (2021 to 2025), KLRS's investing cash flow has grown at a -67.4% compound annual growth rate (CAGR), from $185.98M to -$19.72M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.